Merck and Moderna maintain a long-standing collaboration on personalized mRNA cancer vaccines, recently reinforced by positive Phase 3 melanoma trial data that drove sharp share gains without any accompanying merger signals. Merck has emphasized disciplined, smaller-scale acquisitions below $15 billion to manage Keytruda patent exposure, while its roughly $333 billion market capitalization and Moderna's $25 billion valuation make a full combination structurally mismatched. No 13D filings, analyst notes, or management commentary point to 2026 discussions, supporting the 98.4% market-implied probability of no announcement. Tail risks remain limited but include an abrupt strategic pivot or unforeseen capital-market pressures that could alter incentives before year-end.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गयामर्क एंड मॉडर्ना विलय/अधिग्रहण की घोषणा 2026 में की गई?
मर्क एंड मॉडर्ना विलय/अधिग्रहण की घोषणा 2026 में की गई?
हाँ
2% संभावना
नया
नया
31 दिस, 2026
हाँ
2% संभावना
नया
नया
31 दिस, 2026
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna maintain a long-standing collaboration on personalized mRNA cancer vaccines, recently reinforced by positive Phase 3 melanoma trial data that drove sharp share gains without any accompanying merger signals. Merck has emphasized disciplined, smaller-scale acquisitions below $15 billion to manage Keytruda patent exposure, while its roughly $333 billion market capitalization and Moderna's $25 billion valuation make a full combination structurally mismatched. No 13D filings, analyst notes, or management commentary point to 2026 discussions, supporting the 98.4% market-implied probability of no announcement. Tail risks remain limited but include an abrupt strategic pivot or unforeseen capital-market pressures that could alter incentives before year-end.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
बाज़ार खुला: Aug 19, 2026, 3:58 PM ET
वॉल्यूम
$411समाप्ति तिथि
31 दिस, 2026बाज़ार खुला
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna maintain a long-standing collaboration on personalized mRNA cancer vaccines, recently reinforced by positive Phase 3 melanoma trial data that drove sharp share gains without any accompanying merger signals. Merck has emphasized disciplined, smaller-scale acquisitions below $15 billion to manage Keytruda patent exposure, while its roughly $333 billion market capitalization and Moderna's $25 billion valuation make a full combination structurally mismatched. No 13D filings, analyst notes, or management commentary point to 2026 discussions, supporting the 98.4% market-implied probability of no announcement. Tail risks remain limited but include an abrupt strategic pivot or unforeseen capital-market pressures that could alter incentives before year-end.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
वॉल्यूम
$411समाप्ति तिथि
31 दिस, 2026बाज़ार खुला
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...Merck and Moderna maintain a long-standing collaboration on personalized mRNA cancer vaccines, recently reinforced by positive Phase 3 melanoma trial data that drove sharp share gains without any accompanying merger signals. Merck has emphasized disciplined, smaller-scale acquisitions below $15 billion to manage Keytruda patent exposure, while its roughly $333 billion market capitalization and Moderna's $25 billion valuation make a full combination structurally mismatched. No 13D filings, analyst notes, or management commentary point to 2026 discussions, supporting the 98.4% market-implied probability of no announcement. Tail risks remain limited but include an abrupt strategic pivot or unforeseen capital-market pressures that could alter incentives before year-end.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया
बाहरी लिंक से सावधान रहें।
बाहरी लिंक से सावधान रहें।
अक्सर पूछे जाने वाले प्रश्न